Alexza Pharmaceuticals Inc. and Biovail Laboratories International SRL have agreed to develop and commercialize Alexza's inhaled antipsychotic AZ-004 (Staccato loxapine) in the U.S. and Canada in a deal worth $130 million. (BioWorld Today)